University IP negotiation: a five-stage spinout project

A research team may have a promising membrane, catalyst, battery chemistry, carbon-monitoring system, or industrial process. The lab has generated the data. The university owns, or claims rights in, the patents. An investor wants to understand the commercial path. And somewhere between those facts sits a Technology Transfer Office (TTO) asking for equity, royalties, patent-cost reimbursement, approval rights, and a plan for turning academic work into a company.

That negotiation is not administrative clean-up. It is the first financing round in disguise.

For climate founders, university IP licensing is particularly messy because the technology often needs years of validation, expensive pilots, regulated deployment, and industrial partners before meaningful revenue appears. A deal that looks tolerable on a spreadsheet can become painful after the company has raised several rounds and still carries the same obligations.

The useful way to approach the process is to treat tech transfer as a five-stage project: identify the invention, assess its commercial value, protect it, promote it, and eventually profit from it. Each stage changes the founder’s leverage—and creates a different set of trade-offs.

1. Identification: define what the university actually owns

The first stage sounds straightforward: identify the invention and the university’s rights in it. In practice, this is where many founders discover that “the technology” is not a single asset.

It may include:

• A patent application filed by the university
• Know-how held by a professor or research group
• Laboratory methods that were never formally documented
• Software, models, datasets, or control systems developed alongside the physical invention
• Improvements made after the original disclosure
• Background IP created before the founder joined the university
• Results generated through sponsored research or government-funded projects
• Third-party materials or licenses embedded in the research

A climate startup can be built around an apparently simple claim—say, a lower-energy separation process—but the commercial product may depend on several layers of IP. The patent might cover the chemistry, while the process conditions, manufacturing method, and control software remain outside it. If the founder negotiates only over the patent number, the company can end up with legal rights to an invention that it cannot actually commercialize.

The TTO’s job traditionally moves through five activities:

1. Identifying the invention and the relevant contributors

2. Assessing its technical and commercial potential

3. Protecting the intellectual property through patents or other measures

4. Promoting the opportunity to potential licensees, investors, and partners

5. Profiting through licensing income, equity value, royalties, or an acquisition

Founders should use this sequence as a map, not as a passive description of the university’s process. At each stage, ask what has been decided, what remains open, and which assumptions could later become a company-killing constraint.

The key document is not always the license itself. It may be the invention disclosure, employment agreement, sponsored-research contract, grant terms, or internal university policy that determines who owns what. A clean chain of title matters to investors, but so does commercial completeness. A patent that cannot be manufactured, sublicensed, or combined with necessary background technology is not a complete commercial asset.

This is also the point to separate the founder’s personal contribution from the university’s institutional rights. Academic founders sometimes assume that because they made the discovery, they can take it with them. Universities generally do not see ownership that way. Employment terms, use of university facilities, research funding, and contribution from other researchers may all affect the position.

That does not mean the university is entitled to every future idea the founder has. It means the boundary needs to be written clearly before the startup begins building value.

2. Assessment: decide whether the IP deserves a company

The second stage is where technical excitement has to meet commercial discipline.

Universities assess inventions partly through patentability and partly through market potential. Founders need to go further. They need to determine whether the protected IP is strong enough, broad enough, and practical enough to support a venture that can survive climate-tech timelines.

A patent is not a business model. It may provide a legal position, but investors and customers will ask harder questions:

• Does the IP solve a painful problem, or merely improve an existing process?
• Is the improvement large enough to justify switching costs?
• Can the technology be manufactured at the required scale?
• Does the company need additional licenses from other institutions?
• Are there incumbent patents that create freedom-to-operate concerns?
• Will the customer buy a product, a project, a performance guarantee, or a long-term service?
• How much capital is required before the company can prove commercial value?
• Does the university’s proposed deal leave enough room for future investors?

This assessment is especially important in climate tech because “better” often has to mean materially better. A technology may reduce emissions but require a new plant, new permitting, new maintenance procedures, and a new procurement process. A customer may agree that the climate benefit is valuable while still refusing to pay for the operational risk.

The founder’s negotiating position improves when the commercial argument is specific. “This could transform industrial decarbonization” is not leverage. A defined use case, a credible first customer, and a clear validation milestone are leverage.

The same is true of capital intensity. If the technology requires a pilot facility, specialized equipment, or long certification cycles, the university should understand that the startup cannot carry a heavy economic burden from the first day. The company may need to preserve cash for engineering, hiring, testing, and customer deployment rather than paying substantial upfront fees.

This is one reason an IP license is often used as a temporary mechanism. The startup may receive rights to validate market demand while formal assignment of the IP is deferred until it reaches agreed funding, technical, or business-plan milestones. That structure can be useful when neither side has enough information to price the technology confidently at formation.

The trade-off is control. A temporary license can protect the founder from paying for an asset before proving demand, but it may also leave the company exposed if the university can terminate, renegotiate, or restrict the rights before the business has reached safety.

The practical question is not simply, “Can we get the IP?” It is, “What rights do we need during the next financing and validation period, and what must be locked in before we spend years building around them?”

A startup should not pay permanent economics for temporary confidence. If the commercial value is still being proven, the agreement needs room for the facts to change.

3. Protection: negotiate the economics before the company is diluted

Once the university decides to protect the invention, the negotiation moves from possibility to economics. This is where founders often focus on one headline number—university equity—and miss the cumulative burden of the agreement.

For deep-tech and life-science spinouts, the University Spin-out Investment Terms, or USIT, Guide recommends university equity stakes of 10–25%. For software-only spinouts, the recommendation is 10% or less. These figures are useful reference points because they challenge the old assumption that a university should automatically take a large ownership position in a new company.

The range still leaves a lot of room for disagreement. Ten percent and twenty-five percent are not variations on the same deal. They produce very different outcomes after fundraising, employee option pools, and later dilution.

A founder should model the cap table across several financing rounds rather than arguing about the initial percentage in isolation. The university’s stake may be non-dilutable for a period, diluted only after a threshold, or subject to different treatment from founder and investor shares. Those details can matter as much as the starting number.

The main economic terms usually sit in four buckets:

Typical royalty rates for university IP licenses generally fall between 0.5% and 5% of sales, but the number alone tells you very little. The definition of “sales” matters. So do sublicensing income, bundled products, minimum annual royalties, geographic scope, and whether royalties apply to every product sold by the company or only to products that use the licensed invention.

For a climate startup, the distinction between product revenue and project revenue can be critical. A company may sell a system, license a process, collect recurring service fees, or receive payments through a special-purpose project company. If the agreement does not anticipate the actual business model, the royalty clause can become a source of conflict precisely when the company starts to scale.

Patent-cost reimbursement deserves equally close attention. Exclusive licenses typically require the startup to reimburse the university for historical and ongoing patent prosecution and maintenance expenses. That is understandable: the university is not expected to fund an international patent portfolio forever. But “all costs” is a blunt phrase unless the agreement gives the company visibility and control.

A founder should seek clarity on:

• Which historical costs are included
• Which jurisdictions are covered
• Who decides whether to file, maintain, or abandon a patent
• Whether the startup can decline a jurisdiction
• Whether costs are capped, budgeted, or approved in advance
• What happens if the university and startup disagree about prosecution strategy
• Whether the company receives rights in a jurisdiction it paid to protect

The negotiation is not about removing every university economic interest. It is about matching the university’s return to the company’s ability to survive.

A staged structure can be more realistic than a single demand: limited equity at formation, modest or deferred upfront fees, milestone payments tied to genuine financing or commercial progress, and royalties that begin only when the relevant revenue exists. The university may receive less immediately, but the company retains enough resilience to reach the point where the asset has real value.

4. Promotion: build a deal that investors and strategic partners can use

The fourth stage—promotion—is often treated as the university’s responsibility. The TTO may list the invention, contact companies, or introduce the research team to potential licensees. For a spinout, promotion is broader. The agreement must be legible to investors, customers, strategic partners, and future acquirers.

This is where assignment and sublicensing rights become central.

Universities often require pre-approval for sublicensing or assignment. The reason is understandable: the institution wants to protect its IP from being transferred to an unsuitable party or stripped of value through a poorly negotiated transaction. But an inflexible approval right can create serious problems for a startup.

A climate company may need to:

• Sublicense manufacturing rights to an industrial partner
• Grant territory-specific rights to a deployment company
• Form a project joint venture
• Transfer the license during an acquisition
• Use the IP as part of a strategic partnership
• Assign rights to a new subsidiary for regulatory or financing reasons

If every one of these actions requires discretionary approval, investors may see the license as an execution risk. The company could spend years developing the technology and still be unable to move quickly when a commercial opportunity appears.

The goal is not to eliminate university oversight. It is to make the approval process predictable. That can mean objective standards, defined response periods, consent not to be unreasonably withheld, and automatic approval for certain categories of transaction. An assignment to an acquiring company, for example, may need different treatment from a transfer to an unrelated shell entity.

The same principle applies to diligence obligations. Exclusive licenses commonly require the startup to meet development milestones, commercialize the technology, and provide regular reports. Those obligations protect against a company shelving the invention, but they must reflect the realities of climate deployment.

A milestone based only on a calendar date may be unreasonable when permitting, feedstock access, grid connection, or industrial customer schedules are outside the startup’s control. Better milestones usually connect to actions the company can actually manage: completing a pilot, raising a defined financing round, submitting a regulatory application, signing a customer agreement, or reaching a technical performance threshold.

There is also a psychological dimension. Founders are often reluctant to push back on a TTO because the office controls access to the asset and may have supported their academic career. That relationship matters, but politeness should not replace clarity. A strained negotiation is uncomfortable. A vague license can be existential.

Use a written deal memo early. Put the material terms in one place before lawyers turn them into dense drafting:

• Field of use
• Territory
• Exclusivity
• Sublicensing
• Assignment
• Equity
• Royalties
• Patent costs
• Milestones
• Improvements
• Publication rights
• Confidentiality
• Termination and cure periods

When the commercial terms are confirmed, final agreements can often be prepared in roughly one to two weeks. That timeline is possible only when the hard decisions have already been made. Legal drafting cannot rescue unresolved business terms; it can only make them longer.

5. Profit: protect the improvements that will become the real company

The fifth stage is profit, but the most important negotiation may concern technology that does not exist yet.

Climate startups rarely commercialize the exact invention described in the original university disclosure. They improve it. They adapt it to different feedstocks, operating conditions, materials, manufacturing processes, and customer environments. The first patent may open the door; the company’s future improvements may determine whether it can walk through it.

The agreement must distinguish between the licensed IP and new IP created by the startup.

This is the ownership trap. A university may seek rights in improvements because they build on academic research. Founders, quite reasonably, want freedom to innovate without handing every future development back to the institution. Investors want to know that the company owns the assets it will spend money creating.

A workable structure may give the startup ownership of improvements made by its employees and contractors, while granting the university a non-exclusive license back for academic research and teaching. That preserves the university’s mission without making the company a temporary custodian of its own engineering work.

The boundaries need to be precise. “Improvements” should not become a catch-all for any invention that resembles the original technology. Consider separating:

• Improvements that require the licensed patent to function
• Improvements that can operate independently
• Manufacturing or process improvements
• Software and control systems
• New applications in different fields
• Data, models, and experimental results
• Improvements created solely by university researchers
• Improvements created jointly by university and company personnel

Joint ownership is usually less tidy than it sounds. It can create uncertainty over licensing, enforcement, prosecution, and future transactions. If joint development is genuinely expected, define who controls patent filing, who pays, who can license the work, and how proceeds are shared.

The founder also needs to understand research rights. Universities often need continued freedom to use the technology for teaching and non-commercial research. That is not automatically a problem. It becomes a problem when “research use” is drafted broadly enough to permit sponsored work for a commercial competitor or to disclose confidential know-how.

Publication rights deserve care as well. Academic researchers may need to publish, while the startup needs time to file patents and protect confidential information. A short review period for patent filing and removal of confidential material is a practical compromise. The company should not attempt to control legitimate academic publication indefinitely, but it should not discover a public paper has destroyed its commercial position either.

The most valuable IP in a spinout may be the improvement the team makes after leaving the lab. If the license treats that work as an afterthought, the company is negotiating away its future before it has one.

Choosing the right path: license, operate, or build a team

Not every academic founder should become a full-time CEO. That is not a failure of ambition. It is a question of fit, timing, and capital intensity.

Academic climate founders generally have three primary routes:

Licensing to an established company can be the right choice when deployment requires infrastructure that a new venture cannot realistically build. A carbon-utilization process may need a major industrial partner. A new energy technology may require a supply chain, certification pathway, and field-service organization that already exist elsewhere.

A full-time spinout makes more sense when the company’s advantage will come from rapid iteration, a focused product strategy, or a difficult-to-transfer body of know-how. The founder’s presence can be essential, but only if the founder is willing to do more than defend the science. Venture building involves customer rejection, hiring, pricing, regulatory work, fundraising, and repeated pivots.

The hybrid path is often underappreciated. An academic founder can retain a university role while hiring an experienced executive, provided the university and investors agree on responsibilities, conflicts, time commitments, and IP boundaries. This can work well, but ambiguity is expensive. Who makes product decisions? Who negotiates with customers? Who owns new IP created by the executive team? What happens when the university’s research priorities conflict with the startup’s commercial priorities?

There is no universally superior route. Licensing is not always inferior to spinning out, and a founder-led company is not automatically more committed or more valuable. The right answer depends on the asset, the market, the founder, and the financing required to reach proof.

The negotiation is a project, not a single meeting

A university IP agreement should be managed with the same discipline as a pilot plant or a fundraising process. Build a timeline, assign owners, and record open questions. The founder should know which terms are essential, which are negotiable, and which can be deferred until more evidence exists.

A practical negotiation sequence looks like this:

1. Map the IP. List patents, know-how, background technology, contributors, funding sources, and dependencies.

2. Define the first commercial use. A narrow field of use can make exclusivity more achievable and prevent unnecessary cost.

3. Model dilution and cash. Include university equity, option pools, future rounds, royalties, milestones, and patent expenses.

4. Set milestone logic. Tie obligations to financing, technical, or commercial events the company can realistically reach.

5. Protect future flexibility. Address improvements, sublicensing, assignment, acquisitions, and strategic partnerships before they become urgent.

6. Choose the operating path. Decide whether the founder will run the company, license the technology, or build a professional team.

7. Turn the deal memo into enforceable language. Make sure the final agreement reflects the commercial understanding rather than quietly changing it.

The founder should also bring the right advisers early. A lawyer who understands university licensing is useful, but legal fluency alone is not enough. The team needs someone who can assess patent scope, freedom to operate, manufacturing dependencies, and the fundraising consequences of the proposed terms.

The TTO is not necessarily the adversary. In many cases, its staff are trying to move a slow institutional process through committees, inventors, patent counsel, and internal approvals. Treating them as partners can make the work easier. Treating them as friends who will fix vague terms later is a mistake.

The hard-earned lesson is less dramatic than the startup mythology suggests: the best university spinouts are not created by winning every negotiation. They are created by making the trade-offs visible early enough to choose them deliberately.

A founder can accept meaningful university equity if the company receives strong, exclusive rights and enough flexibility to raise capital. A royalty can be manageable if it applies to the right revenue and begins at the right point. Patent reimbursement can be fair if the startup controls what it funds. Academic research rights can coexist with commercial exclusivity if the boundary is real.

What does not work is pretending that these obligations are minor because the technology is exciting.

Climate ventures already face long validation cycles, uncertain markets, and heavy capital demands. The IP agreement should not add avoidable fragility. Negotiate for the company you will have after the next funding round, the first pilot, and the first serious partnership—not only for the laboratory project standing in front of you today.

That is the difference between obtaining a license and building a spinout.